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Saudi ArabiaAbstract Objective: To assess community pharmacists’ knowledge, behaviors and experiences
relating to Adverse Drug Reaction (ADR) reporting in Saudi Arabia.
Methods: A cross-sectional study was conducted using a validated self-administered question-
naire. A convenience sample of 147 community pharmacists working in community pharmacies
in Riyadh, Saudi Arabia.
Results: The questionnaire was distributed to 147 pharmacists, of whom 104 responded to the
survey, a 70.7% response rate. The mean age of participants was 29 years. The majority
(n= 101, 98.1%) had graduated with a bachelorette degree and worked in chain pharmacies
(n= 68, 66.7%). Only 23 (22.1%) said they were familiar with the ADR reporting process, and
only 21 (20.2%) knew that pharmacists can submit ADR reports online. The majority of the par-
ticipants (n= 90, 86.5%) had never reported ADRs. Reasons for not reporting ADRs most impor-
tantly included lack of awareness about the method of reporting (n= 22, 45.9%), misconception
412 M.A. Mahmoud et al.that reporting ADRs is the duty of physician and hospital pharmacist (n= 8, 16.6%) and ADRs in
community pharmacies are simple and should not be reported (n= 8, 16.6%). The most common
approach perceived by community pharmacists for managing patients suffering from ADRs was to
refer him/her to a physician (n= 80, 76.9%).
Conclusion: The majority of community pharmacists in Riyadh have poor knowledge of the
ADR reporting process. Pharmacovigilance authorities should take necessary steps to urgently
design interventional programs in order to increase the knowledge and awareness of pharmacists
regarding the ADR reporting process.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Adverse drug reactions (ADRs) are the most common cause of
morbidity, mortality and poor economic outcomes (Pirmoha-
med et al., 2004; Patel et al., 2007). Therefore, post-marketing
surveillance is very important for monitoring the risk and ben-
eﬁts of pharmaceutical products after they have been released
on the market (Edlavitch, 1988). As an initiative to encourage
and monitor ADR reporting, the Saudi Food and Drug
Authority (SFDA) has recently established a National Phar-
macovigilance Center that has made online reporting forms
and papers forms available to encourage ADR reporting by
public and healthcare professionals (National Pharmacovigi-
lance Centre, 2012).
Traditionally, the role of the pharmacist was limited to
the preparation and dispensing of drugs prescribed by the
physician. Recently, the role of the pharmacist has expanded
to other aspects of patient care. These roles include report-
ing ADRs, improving patients’ health, and economic out-
comes (Hepler and Strand, 1990; Manley and Carroll,
2002; Kane et al., 2003). Pharmacists can play an important
role in ADR reporting and pharmacovigilance by increasing
the number as well as the quality of submitted reports (Kees
et al., 2004; Gedde-Dahl et al., 2007). However, in many
countries the knowledge of pharmacists about pharmacovig-
ilance and ADR reporting is poor and the rate of reporting
is low (Oreagba et al., 2011; Su et al., 2010; Vessal et al.,
2009; Toklu and Uysal, 2008; Lee et al., 1994). The scenario
in Saudi Arabia is the same as in other countries. A recent
Saudi study reported lower awareness of the ADR reporting
program and a poor reporting rate (13.2%). Barriers to
ADR reporting identiﬁed by this study included, most com-
monly, a lack of knowledge about where and how to report
ADRs, and unavailability of ADR reporting forms (Bawa-
zir, 2006).
Assessing the knowledge, behaviors and experiences of
community pharmacists relating to spontaneous reporting
of ADRs is very important. When pharmacists have sufﬁ-
cient knowledge of the ADR reporting process, they can im-
prove other healthcare professionals’ knowledge about ADR
reporting (Khalili et al., 2012). In Saudi Arabia, studies con-
ducted to assess pharmacists’ knowledge, behaviors and
experiences relating to ADR reporting are limited (Bawazir,
2006) and were conducted before the establishment of the
National Pharmacovigilance Centre. Therefore, the aims of
the current study were to assess the knowledge, behaviors
and experiences of community pharmacists regarding the
reporting of ADRs.2. Methods
2.1. Study design and setting
This was a cross-sectional study conducted among a conve-
nience sample of community pharmacists from Riyadh, Saudi
Arabia.
2.2. Study tool
The questionnaire comprised 21 questions (Appendix 1). The
ﬁrst part consisted of two questions, one closed-ended and one
open-ended. This part was designed to understand community
pharmacists’ familiarity with the ADR reporting process. The
second part consisted of four questions, two open-ended and
two close-ended, which used a four-point scale ranging from
‘‘never’’ to ‘‘frequently’’. The third part of the questionnaire con-
sisted of four open-ended questions andone close-ended question
designed to measure community pharmacists’ experiences with
ADRs. In the fourth part of the survey, patients’ knowledge
regarding counseling about ADRs was measured with a ﬁve-
point scale ranging from ‘‘never’’ to ‘‘frequently’’. Three experts
in the ﬁeld were asked to provide comments regarding the ques-
tionnaire conciseness, clarity and relevance. Their comments
were taken into consideration and the ﬁnal survey was prepared.
The questionnaire language was English.
2.3. Data collection and ethical consideration
A pharmacy student visited each pharmacy and invited com-
munity pharmacists to participate in the study after explaining
the aims of the study. A written consent form was obtained
from each participant who wished to participate in the study.
Participants were told that all information provided was com-
pletely conﬁdential and the results would be presented
anonymously.
2.4. Data analysis
Descriptive statistics were used to analyze the data (frequency
and percentages; mean ± standard deviation). Statistical anal-
ysis was performed using the Statistical Package for Social Sci-
ence (SPSS) Software for Windows, (version 20.0).
3. Results
The survey was distributed to 147 pharmacists; however only
104 surveys were collected, giving a response rate of 70.7%.
Table 1 Demographic Characteristics of 104 community
pharmacists.
Frequency (%)
Age (Mean) 29
Number of years of
experience as a community
pharmacist (Mean ± SD)
3.4 ± 2.4
Number of prescriptions
dispensed per week (Median)
70
Community pharmacist qualiﬁcation
Bachelor 101 98.1
Diploma 1 0.9
PhD 1 0.9
Category of community pharmacy
Independent pharmacy 14 13.7
Chain Pharmacy 68 66.7
Hospital pharmacy 20 19.6
Country of graduation
Egypt 80 79.4
Yemen 10 9.9
Syria 5 4.9
Sudan 4 3.9
Jordan 1 0.9
India 1 0.9
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nity pharmacists in this study were predominantly graduated
from Egypt (n= 80, 79.4%) and most (n= 101, 98.1%) had
completed their bachelorette degree (Table 1). The majority
of participants were employed in chain community pharmacies
(n= 68, 66.7%).
3.1. Community pharmacists’ knowledge about the ADR
reporting system in Saudi Arabia
Only 23 (22%) of the participants said that they were familiar
with the ADR reporting process (Fig. 1). Those who said that
they were aware of such reporting were asked if they knew the
regulatory body to which ADRs should be reported. Answers
were provided by 18 participants which included the Ministry
of Health (MOH) (n= 7), SFDA (n= 6), government hospi-
tals (n= 1), hospital drug information centre (n= 2) and
unspeciﬁed internet websites (n= 2). However, about 80%
of the pharmacists did not know that they could report ADRs0.% 
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Figure 1 Are you familiar with ADR reporting process (i.e. how
and where to submit ADR reports) in Saudi Arabia?through an online system. The responses to knowledge items
are illustrated in Table 2.
3.2. Community pharmacists’ behavior toward ADR reporting
Only 13 (12.5%) of the participants said they reported ADRs
when they occurred. The majority of participants (n= 91,
87.5%) did not report ADRs. Of these 91 participants, 48 pro-
vided reasons for not reporting ADRs; 22 (45.9%) said that
they were not aware of the method of reporting, 8 (16.6%) said
that ADR reporting was the duty of physicians and hospital
pharmacists, 8 (16.6%) said that most ADRs in community
pharmacy are minor and should not be reported, 4 (8.3%) said
that all ADRs are familiar and already reported in the medica-
tion leaﬂet, 3 (6.3%) said they did not have a computer or
internet access in the pharmacy to report ADRs, and 3
(6.3%) said they did not report ADRs because of workload.
Table 3 summarizes community pharmacist’s responses to
behavior items.
3.3. Community pharmacists’ experiences with ADRs
Table 2 summarizes the experiences and actions taken by phar-
macists when a patient with an ADR seeks advice from them
(Table 4). The most common approach perceived by commu-
nity pharmacist to manage patients suffering from ADRs
was to refer him/her to a physician. The most common side ef-
fects seen during the participants’ daily practice were diarrhea
(n= 14, 13%), allergy (n= 8, 7.5%), and headache (n= 6,
5.7%). The most common drug classes believed to be associ-
ated with ADRs were antibiotics (n= 22, 27.5%), analgesics
(n= 11, 13.7%), and antihypertensives (n= 5, 6.2%).
4. Discussion
We performed a cross-sectional assessment of knowledge,
experience and behaviors of community pharmacists about
the reporting of ADRs in Saudi Arabia. Our results have re-
vealed that pharmacists have poor knowledge of ADR report-
ing, few pharmacists have reported ADRs, and the majority
are not aware of the process of ADR reporting. Reasons for
not reporting ADRs mainly included lack of awareness about
the method of reporting, disclaiming responsibility for ADR
reporting, and the belief that most ADRs in community phar-
macies are minor and should not be reported.
Several previous studies have documented a lack of knowl-
edge in community pharmacists about ADR reporting similar
to our ﬁndings. The rate of ADR reporting by pharmacists in
various countries has been reported to vary from 3% to 14.7%
(Oreagba et al., 2011; Su et al., 2010; Vessal et al., 2009; Toklu
and Uysal, 2008; Lee et al., 1994). A previous study from Saudi
Arabia reported a lower level of awareness about the process
of ADR reporting compared to our ﬁndings (13.2% vs.
22%) Bawazir, 2006. Regarding knowledge about where
ADRs can be submitted, most pharmacists claimed that they
had submitted ADRs to the Ministry of Health and SFDA.
In the study by Bawazir, 2006, the majority of pharmacists sur-
veyed claimed that they had submitted ADRs to both the
pharmaceutical company and the Ministry of Health. One of
the most serious barriers to reporting ADRs identiﬁed in this
study is that pharmacists do not take responsibility for report-
Table 2 Community Pharmacist Knowledge about ADR patient counseling.
Question Never Rarely Sometimes Frequently Always
How often do you ask your patient if he/she is
allergic to medications
2 (1.9%) 6 (5.8%) 24 (23.1%) 26 (25%) 46 (44.2%)
How often do you ask a female if she is
pregnant when dispensing teratogenic/
abortive medication
0 1 (1 %) 4 (4.8%) 24 (23.1%) 75 (72.1%)
How often do you ask a female if she is
lactating when dispensing medication that is
excreted in the mother milk and might harm
the baby
0 5 (4.8%) 1 (1%) 27 (26%) 71 (68.3%)
How often do you counsel your patients
about ADRs that they may experience from
their medication?
1 (1%) 6 (5.8%) 19 (18.3%) 26 (25%) 52 (50%)
Table 3 Community pharmacist behavior toward ADR reporting.
Item Never Rarely sometimes Frequently
How often do you discuss an ADR with your pharmacist colleague? 5 (4.8%) 14 (13.5%) 47 (45.2%) 38 (36.5%)
How often do you discuss an ADR with the prescriber? 25 (24%) 21 (20%) 31 (30%) 27 (26%)
Table 4 Community pharmacist experience with ADR reporting.
Item Yes No
If a patient comes to you in the pharmacy complaining of a side eﬀect or adverse reaction what measure do you adopt to comfort the patient?
Give him a medicine to treat his condition 38 (36.5%) 66 (63.5%)
Refer him/her to see a physician 80 (76.9%) 24 (23.1%)
Just ask him to stop taking that medicine 39 (37.5%) 65 (62.5%)
Give him/her a medicine to treat the condition and ask him/her to stop the
medication causing the ADRs
18 (17.3%) 86 (82.7%)
414 M.A. Mahmoud et al.ing. Previous studies had shown that pharmacists can make a
major positive contribution to the quality and number of
ADRs reported (Kees et al., 2004; Gedde-Dahl et al., 2007;
Khalili et al., 2012).
The current study has several limitations. The survey
included community pharmacists’ from one city in Saudi
Arabia which limits its generalizability. In the current study,
some pharmacists indicated that they did not have internet
connection in their pharmacy; this may have partially
contributed to the underreporting of ADRs. Also, community
pharmacists’ heavy workload might have limited the response
rate.
Although there is a reporting system in Saudi Arabia that
deals with ADRs in both paper and electronic format, the
majority of community pharmacists are unaware of whereand how to report ADRs. Community pharmacists believe
that ADR reporting is the responsibility of physicians and hos-
pital pharmacists. A computer and access to an internet con-
nection should be available in all community pharmacies to
help the pharmacist report ADRs online. Pharmacovigilance
authorities in Saudi Arabia should utilize interventional pro-
grams that have been shown to increase the knowledge and
awareness of ADR reporting in other countries (Gedde-Dahl
et al., 2007; Granas et al., 2007; Sevene et al., 2008; Irujo
et al., 2007). Involvement of pharmacy students in community
pharmacy internships may increase the awareness of future
pharmacists regarding ADR detection and reporting (Chris-
tensen et al., 2011). In addition, training programs in pharma-
covigilance and spontaneous reporting may also help to
minimize the rate of underreporting.
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